The product, which is the generic version of Pfizer’s Zosyn injection, is a combination of penicillin-class antibacterial and beta-lactamase inhibitor.
According to IMS Health, Piperacillin and Tazobactam for Injection USP, 3.375g single-dose vials had US sales of about $72.1m for the 12 months ended on 30 June 2015.
The launch of this product adds to Mylan’s growing portfolio of over 145 injectable products available to patients in the US across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/pain management and cardiovascular.
Around 267 of Mylan ANDAs that represent $101.3bn in annual sales are still awaiting clearances from the FDA, with 50 of them being potential first-to-file opportunities, signifying $33.4bn in annual brand sales, for the year ending 31 December 2014.
The company provides a portfolio of more than 1,400 generic medications as well as a range of antiretroviral therapies to around 50% of HIV/AIDS patients in developing countries.